TG-1501 (ANTI-PD-L1)

TG-1501 is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors. 

Cancer cells elude anti-tumor immunity through multiple mechanisms, including upregulated expression of ligands for inhibitory immune checkpoint receptors. The immune checkpoint Programmed Death-1 receptor (PD-1) on the surface of T-cells triggers the transient downregulation of T-cell function when engaged by its ligands (PD-L1 and PD-L2). This pathway helps control immune activity in settings of chronic antigen exposure. Clinical studies have shown that blockade of the PD-1/PD-L1 pathway by monoclonal antibodies can enhance the immune response and result in anti-tumor activity. PD-L1 is the primary PD-1 ligand that is up-regulated in tumors, where it can inhibit cytokine production, the cytolytic activity of PD-1+, and tumor-infiltrating CD4+ and CD8+ T cells. These properties make PD-L1 a target for cancer immunotherapy. The clinical availability of monoclonal antibodies blocking PD-1 or PD-L1 has opened an unprecedented opportunity in the treatment of cancer. This strategy has already achieved successful results in several tumor types, including certain types of lymphoma. TG-1501 is currently under evaluation in a Phase 1 dose escalation clinical trial in subjects with recurrent or advanced cancers including classical Hodgkin lymphoma.


The company has recently brought TG-1501, its anti-PD-L1 monoclonal antibody into Phase 1 development.